Management of progressive metastatic neuroendocrine tumors (NETs) is challenging due to limited treatment options. As a rare disease, newer drugs and large registrational clinical trials are infrequent. The recent use of immune checkpoint inhibitors has exploded into the field of oncology but unfortunately, many of the rare tumors are untouched by this immune-oncology revolution. This situation stems from a dearth of viable NET models for pre-clinical immune studies.

中文翻译：

---

免疫肿瘤学和神经内分泌肿瘤

由于治疗方案的限制，进展性转移性神经内分泌肿瘤（NETs）的管理具有挑战性。作为一种罕见的疾病，很少有新药和大型注册临床试验。免疫检查点抑制剂的最新用途已进入肿瘤学领域，但不幸的是，这种免疫肿瘤学革命并未触及许多罕见的肿瘤。这种情况源于缺乏用于临床前免疫研究的可行NET模型。